Literature DB >> 15878282

3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter.

Werner J Geldenhuys1, Paul R Lockman, Tiffany H Nguyen, Cornelis J Van der Schyf, Peter A Crooks, Linda P Dwoskin, David D Allen.   

Abstract

Previously, we have developed 3D-QSAR models of the blood-brain barrier (BBB) choline transporter, a transport system that may have utility as a vector for central nervous system drug delivery. In this study, we extended the model by evaluating five bis-azaaromatic quaternary ammonium compounds for their affinity for the choline binding site on the BBB-choline transporter. The compounds, and their affinities for the transporter, were then incorporated into our existing molecular model, in order to update our knowledge on the molecular recognition factors associated with interaction of ligands at the choline binding site. The current compounds are structurally related to previous substrates that we have evaluated, but offer additional three dimensional aspects compared to the series of compounds previously utilized to define the original models. The compounds showed good affinity for the BBB-choline transporter, exhibiting inhibition constants ranging from 10 to 68 microM, as determined by the in situ rat brain perfusion method. Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) methods were used to build the new 3D QSAR models. When the new bis-azaaromatic quaternary ammonium compounds were included in the model, the best cross-validated CoMFA q2 was found to be 0.536 and the non-cross-validated r2 was 0.818. CoMSIA hydrophobic cross-validated q2 was 0.506 and the non-cross-validated r2 was 0.804. This new model was able to better predict BBB-choline transporter affinity of hemicholinium-3 (predicted 65 microM, actual 54 microM), when compared to an earlier model (predicted 316 microM).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878282     DOI: 10.1016/j.bmc.2005.04.020

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer.

Authors:  Vinay K Venishetty; Werner J Geldenhuys; Tori B Terell-Hall; Jessica I G Griffith; Gregory R Sondag; Fayez F Safadi; Paul R Lockman
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

2.  Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.

Authors:  Guangrong Zheng; Zhenfa Zhang; Paul R Lockman; Werner J Geldenhuys; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

3.  Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Guangrong Zheng; Marharyta Pivavarchyk; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-11-24       Impact factor: 2.823

4.  Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter.

Authors:  Werner J Geldenhuys; Vamshi K Manda; Rajendar K Mittapalli; Cornelis J Van der Schyf; Peter A Crooks; Linda P Dwoskin; David D Allen; Paul R Lockman
Journal:  Bioorg Med Chem Lett       Date:  2009-12-28       Impact factor: 2.823

5.  bis-Pyridinium cyclophanes: novel ligands with high affinity for the blood-brain barrier choline transporter.

Authors:  Zhenfa Zhang; Paul R Lockman; Rajendar K Mittapalli; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-08-30       Impact factor: 2.823

6.  Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.

Authors:  Zaineb A Fadhel Albayati; Linda P Dwoskin; Peter A Crooks
Journal:  Drug Metab Dispos       Date:  2008-07-10       Impact factor: 3.922

Review 7.  Molecular determinants of blood-brain barrier permeation.

Authors:  Werner J Geldenhuys; Afroz S Mohammad; Chris E Adkins; Paul R Lockman
Journal:  Ther Deliv       Date:  2015-08-25

8.  The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.

Authors:  Shafiqur Rahman; Nichole M Neugebauer; Zhenfa Zhang; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Eur J Pharmacol       Date:  2008-10-26       Impact factor: 4.432

9.  Region-specific effects of N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.

Authors:  S Rahman; Z Zhang; R L Papke; P A Crooks; L P Dwoskin; M T Bardo
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

10.  A choline derivate-modified nanoprobe for glioma diagnosis using MRI.

Authors:  Jianfeng Li; Shixian Huang; Kun Shao; Yang Liu; Sai An; Yuyang Kuang; Yubo Guo; Haojun Ma; Xuxia Wang; Chen Jiang
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.